MedTrace Logo

Comparative Effectiveness Study for Bipolar Disorder

NCT01331304 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 482

Last updated 2018-04-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the effectiveness of lithium and quetiapine for the treatment of individuals with bipolar disorder.

Conditions

Interventions

DRUG

Lithium

600-900mg per day over 6 months

DRUG

Quetiapine

100-800mg a day over 6 months

Sponsors & Collaborators

  • Agency for Healthcare Research and Quality (AHRQ)

    collaborator FED

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Andrew A Nierenberg, MD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
68 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2013-04-30
Completion
2013-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01331304 on ClinicalTrials.gov